Management Team

Management Team

Daniel J. O'Connor

President, Director & Chief Executive Officer

Mr. O’Connor is the Chief Executive Officer of OncoSec Medical, Inc., a biopharmaceutical company developing intratumoral cancer immunotherapies.

Christopher G. Twitty, PhD

Chief Scientific Officer

Dr. Twitty brings over 20 years of experience in tumor immunology and cancer immunotherapy, including the discovery and development of OncoSec’s leading clinical immune monitoring and biomarker program.

Sara Bonstein, MBA

Chief Financial Officer & Chief Operating Officer

Ms. Bonstein brings more than 15 years of operational and financial leadership in the life sciences industry with Advaxis, Inc., Eli Lilly & Company, ImClone Systems, and Johnson & Johnson.

Kellie Malloy Foerter

Chief Clinical Development Officer

Ms. Malloy Foerter brings nearly thirty years of experience in clinical research with Syneos Health, inVentiv Health (previously PharmaNet), and Covance.

Keir Loiacono

Vice President Legal and Corporate Development, Chief Compliance Officer

Mr. Loiacono brings more than 17 years of success across the life sciences and medical device industries, having held commercial, legal and business roles.

Robert W. Ashworth, Ph.D

Senior Vice President, Regulatory, Quality and CMC

With more than 35 years of experience in the pharmaceutical industry, Dr. Ashworth is well-versed in drug development and global regulatory strategies and has made significant contributions to the FDA approval of 12 new drugs.

John Rodriguez

Vice President, Product Engineering

Mr. Rodriguez is a leader in product development with over 30 years of experience heading teams in the design, development and manufacture of products for the biomedical industry.

Board of Directors

DANIEL J. O’CONNOR

CEO & DIRECTOR

AVTAR DHILLON, M.D. 

CO-FOUNDER / CHAIRMAN

PUNIT DHILLON

CO-FOUNDER / DIRECTOR

JIM DEMESA, MD, MBA. 

DIRECTOR

JOON KIM. 

DIRECTOR

ROBERT E. WARD

DIRECTOR

MARGARET R. DALESANDRO, PHD 

DIRECTOR

Scientific Advisory Board

RICHARD HELLER, PH.D. 

Dr. Heller has over 25 years of experience in evaluating effects of electric pulses on biological systems. He is recognized as a pioneer on the use of electrotransfer for drug and gene delivery.

IACOB MATHIESEN, PH.D. 

Dr. Mathiesen has a PhD from University of Oslo, Norway. He was a co-founder of Inovio AS, Norway and inventor on numerous electroporation related patents covering devices and methods for gene based immune therapy.

SOLDANO FERRONE, MD, PH.D. 

Dr. Ferrone leads a research program focused on the characterization of escape mechanisms deployed by tumor cells to avoid immune-mediated recognition and destruction. 

Scientific Advisory Board

ALAIN ALGAZI M.D. 

Associate Professor, Department of Medicine (Hematology / Oncology), UCSF Program Leader, UCSF Head and Neck Medical Oncology Melanoma Specialist, UCSH Medical Center

ROBERT H.I. ANDTBACKA, M.D., CM, FACS, FRCSC

Associate Professor, Surgical Oncology Department of Surgery University of Utah, Co-Director Melanoma Program, Co-Director Melanoma Clinical Research Program Huntsman Cancer Institute

AXEL HAUSCHILD, M.D.,Ph.D  

Professor of Dermatology, Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany

GEORGINA LONG, BSc, Ph.D., MBBS, FRACP 

Conjoint Medical Director Melanoma Institute Australia, Professor of Melanoma Medical Oncology and Translational Research Melanoma Institute Australia, University of Sydney, Royal North Shore Hospital

PAMELA MUNSTER, M.D. 

Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit, Co-leader of the Center for BRCA Research, and Leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center

WALTER J URBA, M.D., Ph.D.  

Medical Oncologist; director of cancer research; co-director, Providence Melanoma Program